BioArctic

BioArctic Net Tangible Assets

The Net Tangible Assets of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 1.97 B SEK. In the previous year, Net Tangible Assets was 894.94 M SEK — a change of 119.80% (higher).

Net Tangible Assets

1.97 BSEK

YoY

119.80%

Last updated:

Net Tangible Assets of BioArctic is 2025 1.97 B SEK. Net Tangible Assets of BioArctic was 2024 894.94 M SEK. It decreases by 119.80% higher compared to the previous year.

The BioArctic Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
1.02 B SEK
Jan 1, 2019
974.50 M SEK
Jan 1, 2020
907.30 M SEK
Jan 1, 2021
788.68 M SEK
Jan 1, 2022
786.24 M SEK
Jan 1, 2023
1.05 B SEK
Jan 1, 2024
894.94 M SEK
Jan 1, 2025
1.97 B SEK
The BioArctic Net Tangible Assets history
YEARNet Tangible AssetsYoY
1.97 BSEK+119.80%
894.94 MSEK-14.49%
1.05 BSEK+33.11%
786.24 MSEK-0.31%
788.68 MSEK-13.07%
907.30 MSEK-6.90%
974.50 MSEK-4.11%
1.02 BSEK+59.75%
636.13 MSEK+946.96%
60.76 MSEK-43.89%
108.28 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Net Tangible Assets of BioArctic is 1.97 B SEK in 2025.

Net Tangible Assets of BioArctic changed from 894.94 M SEK to 1.97 B SEK, representing a 119.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets BioArctic since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic